China renews crackdown on corruption in healthcare

At least 177 officials reportedly under investigation amid revival of Xi Jinping’s decade-old anti-corruption drive

China’s graft-busters have set their sights on the country’s healthcare sector, in what has been described as the biggest crackdown on corruption in the history of the industry.

At least 177 hospital bosses and Chinese Communist party (CCP) secretaries have been placed under investigation this year according to local media reports – more than double the number last year. In a press conference on Tuesday, the National Health Commission (NHC) said the campaign would focus on people who had used their position to procure kickbacks and corruption in the pharmaceutical sector, the state tabloid the Global Times reported.

Continue reading...

Indian doctors rebel over diktat to prescribe cheaper drugs

Indian Medical Association says that testing is substandard in the manufacture of generic medicines with ‘no guarantee of quality’

Indian doctors have been told they can no longer prescribe branded drugs for their patients, provoking vehement protest from the Indian Medical Association [IMA].

New government guidelines demand a wider use of generic drugs, which are 30%-80% cheaper, reducing the cost of medicines for millions. When doctors prescribe a medicine for fever, for example, they will have to give paracetamol, not drugs such as Panadol or Calpol. Doctors liken this to “running trains without tracks” because the quality of generic drugs cannot be guaranteed.

Continue reading...

Children’s medicines in short supply across Australia as cold and flu cases continue to rise

Chemists say global supply issues and increased demand behind lack of stock, but antibiotic substitutions are available

Australian parents are struggling to find medicines for their children as cold and flu cases continue to rise this winter, according to health experts and practitioners.

As part of ongoing medicine shortages caused by global supply problems since the Covid pandemic, children’s medicine has become a “hotspot” in the last couple of weeks.

Sign up for Guardian Australia’s free morning and afternoon email newsletters for your daily news roundup

Continue reading...

Sciensus’s licence partly suspended after death of cancer patient

Regulator acts after firm paid millions by NHS for healthcare gave patients wrong chemotherapy dose

Britain’s health regulator has partly suspended the manufacturing licence of Sciensus, a private company paid millions by the NHS to provide vital medicines, after the death of a cancer patient who was given the wrong dose of chemotherapy.

The Medicines and Healthcare products Regulatory Agency (MHRA) said it had taken “immediate” action under regulation 28 of the Human Medicines Regulations 2012 law “where it appears to the MHRA that in the interests of safety the licence should be suspended”.

Continue reading...

AstraZeneca considers spinning off its China business

UK’s largest stock-market-listed firm weighs up Hong Kong or Shanghai listing to shield it from geopolitical tensions

AstraZeneca is considering spinning off its business in China and listing it in Hong Kong or Shanghai to shield the multinational drugmaker from geopolitical tensions.

Britain’s largest stock-market-listed company has drawn up the plans in attempt to protect its business from the fallout from increasing tensions between China and the US and its allies.

Continue reading...

Pharmacy Guild accused in Senate of using patient contact details to protest Labor dispensing changes

Guild says it adheres to all relevant privacy laws as medical association says patient’s personal information is ‘sacrosanct, not a plaything’

The health department has expressed concern the Pharmacy Guild appears to be using patient contact details from its “Find a Pharmacy” website to campaign against 60-day medicine dispensing.

Meanwhile, the Australian Medical Association has labelled the Pharmacy Guild’s opposition to the new rules a “sick joke”.

Sign up for Guardian Australia’s free morning and afternoon email newsletters for your daily news roundup

Continue reading...

Injectable HIV-prevention drug to be made in South Africa for the first time

Indian drug company to make cheaper generic version of CAB-LA, potentially protecting millions of people in Africa from the virus

An affordable version of a groundbreaking HIV-prevention drug will be made in South Africa for the first time, potentially giving millions of people at risk of HIV infection in Africa access to a two-monthly jab that can almost eliminate their chances of contracting the virus.

The Indian drug company Cipla confirmed that a generic version of the prophylaxis, long-acting cabotegravir (CAB-LA), would be manufactured at its plants in Benoni, near Johannesburg, or Durban.

Continue reading...

Indian study reveals about 3% of drugs ‘substandard’ amid official crackdown

In wake of children’s cough syrup scandal, an expert says regulatory system is ‘grossly understaffed and underfunctional’

About 3% of drugs routinely taken by Indians for ailments such as hypertension, bacterial infections and allergies are “substandard”, according to a study of samples taken from factories by government inspectors.

Officials have been carrying out random checks on factories after a scandal over Indian-made cough syrups linked to the deaths of children, mostly in countries in Africa.

Continue reading...

UK and Europe are falling behind US and China in biotech, says AstraZeneca boss

Pascal Soriot says decline in startups across Europe differs markedly from ‘explosion’ of firms and clinical trials in China

The boss of Britain’s biggest drugmaker has said that the UK and the rest of Europe are falling behind China and the US in the creation of biotech firms and clinical trials of new medicines.

Pascal Soriot, chief executive of AstraZeneca, said that while China had seen an “explosion of biotech companies”, and a “rapid expansion of clinical trials” that puts it ahead of the US, the UK and EU had posted declines.

Continue reading...

Two-for-one prescription changes to save Australian patients more than $1.6bn

Changes to be included in budget will slash costs for GP visits and medicines but pharmacists likely to push back against new policy

Millions of Australians will be able to buy two months’ worth of medicine for the price of a single prescription, in a move that will slash out-of-pocket costs for GP visits and medicines.

The health minister, Mark Butler, announced the change on Wednesday, suggesting it will save patients more than $1.6bn over the next four years.

Sign up for Guardian Australia’s free morning and afternoon email newsletters for your daily news roundup

Continue reading...

AstraZeneca overtakes Pfizer as crunch week for UK pharma looms

Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results

Nearly a decade after AstraZeneca fended off a hostile takeover approach from US rival Pfizer, the British drug firm has overtaken the Viagra maker in terms of market value, marking a significant moment in its turnaround – and for UK plc.

In a week when AstraZeneca and Britain’s second-biggest pharma firm GSK release their latest quarterly results and the main industry body, the Association of the British Pharmaceutical Industry holds its annual conference, all eyes will be on what pharma executives say about the UK as a place to operate and invest in.

Continue reading...

Novartis scraps cholesterol drug trial in blow to UK life sciences ambitions

Swiss firm’s withdrawal from Leqvio trial with NHS dents government plans to attract post-Brexit research and investment

The Swiss pharmaceutical firm Novartis has ditched plans for a large clinical trial in the UK, in a further blow to the government’s efforts to make Britain an attractive place for research and investment after Brexit.

The company decided to scrap the Orion-17 trial of its cholesterol-lowering drug Leqvio, involving 40,000 patients in partnership with NHS England.

Continue reading...

Drugmaker Eli Lilly says it will cut insulin prices by 70%

Move comes amid criticism of healthcare companies over rising costs of insulin, as CEO says cuts ‘should be the new standard’

Eli Lilly will cut list prices by 70% for its most commonly prescribed forms of insulin, Humalog and Humulin, beginning from the fourth quarter of this year, the drugmaker said on Wednesday.

The move comes amid criticism of healthcare companies by US lawmakers over rising costs of insulin, with Joe Biden’s signature Inflation Reduction Act including a $35 cap on insulin for those enrolled in Medicare health insurance plans.

Continue reading...

US moves to simplify Covid vaccines into yearly dose to target variants

The FDA asked its scientific advisers on Thursday to help chalk out plan to move to a flu shot-like schedule for coronavirus

The US is poised to make Covid-19 vaccinations more like a yearly flu shot, a major shift in strategy despite a long list of questions about how to best protect against a still rapidly mutating virus.

The Food and Drug Administration asked its scientific advisers on Thursday to help lay the groundwork for switching to once-a-year boosters for most Americans – and how and when to periodically update the shots’ recipe.

Continue reading...

FDA under fire over approval of Alzheimer’s drug Aduhelm

House of Representatives’ report details ‘corporate greed’ and ‘atypical review process’ preceding agency’s approval of Biogen’s drug

US drug regulators failed to follow their own guidance and practices when they approved the controversial Alzheimer’s drug Aduhelm, a congressional report said on Thursday.

The US food and drug administration’s (FDA) process of approval, it said, had been “rife with irregularities”, and the FDA’s interactions with maker Biogen had been “atypical”.

Continue reading...

Gene therapy at $3.5m a dose approved for US adults with hemophilia B

Hemgenix frees patients from repeated treatments but initial cost makes it most expensive medicine in the world

US drug regulators have approved a one-off gene-therapy treatment for adults with the genetic blood disorder hemophilia B that frees patients from repeated treatments but costs $3.5m a dose, making it the most expensive medicine in the world.

The US Food and Drug Administration (FDA) approved CSL Behring’s hemophilia B gene therapy Hemgenix on Tuesday. It cuts the number of bleeding events expected over the course of a year by over half, a study found, and reduces 94% of patients from the need for regular infusions to control the condition.

Continue reading...

Pill to prevent pre-eclampsia gets UK fast track for development

Exclusive: MHRA grants innovation passport to drug that could prevent women from developing condition

A new pill that could prevent pre-eclampsia has become the first pregnancy drug to be fast-tracked for development by the UK’s drug regulator.

Scientists at MirZyme Therapeutics, a biopharmaceutical company, believe they have developed a drug that when given to women from 20 weeks of pregnancy could stop them developing the condition.

Continue reading...

Indonesia bans sale of syrup medicines after at least 99 child deaths

Country investigating 206 cases of kidney injury that could be linked to ingredients in liquid medicines

Indonesia has banned the sale of all syrup medicines as it investigates the deaths this year of nearly 100 children, warning that the liquids may contain ingredients linked to fatal kidney injuries.

The move comes just weeks after the World Health Organization issued an alert over four Indian-made cough syrups that it said were potentially linked with acute kidney injuries and the deaths of 70 children in the Gambia.

Continue reading...

Campaigners celebrate as V&A severs Sackler links over opioids cash

London museum bows to years of pressure and removes signs acknowledging the family behind the OxyContin crisis

Campaigners calling for the name Sackler to be dropped from cultural landmarks are celebrating this weekend. Their smiles mark five years of demonstrations and dramatic stunts as another major arts institution – London’s Victoria and Albert Museum – takes down signs acknowledging the financial contribution from this wealthy family.

The museum is dropping it controversial ties with the Sackler family, descendants of US makers of addictive opioid prescription drugs. It’s a victory for the campaign group Sackler P.A.I.N, which staged a dramatic public protest at the gallery in November 2019. The group, led by American artist Nan Goldin, argued that donations from the family that founded now-bankrupt Purdue Pharma, maker of the painkiller OxyContin, were a moral stain on cultural institutions that accepted them.

Continue reading...

Limits on paracetamol purchases could reduce injury and death from overdoses, expert panel says

TGA report recommends reduced packet sizes and restricting over-the-counter sales of the drug to people 18 and over

The size of paracetamol packets sold in supermarkets could be reduced and limits introduced on the number of boxes that can be bought, in a bid to reduce injury and death from intentional overdoses.

The recommendations are contained in an independent expert report published by Australia’s drugs regulator, the Therapeutic Goods Administration. The report found rates of intentional paracetamol overdose were highest among adolescents and young adults, and more common among women and girls.

Sign up to receive an email with the top stories from Guardian Australia every morning

Crisis support services can be reached 24 hours a day: Lifeline 13 11 14; Suicide Call Back Service 1300 659 467; Kids Helpline 1800 55 1800; MensLine Australia 1300 78 99 78; Beyond Blue 1300 22 4636

Continue reading...